Organon Launches Two Biosimilars In Canada As Sales Slide
Avastin And Herceptin Rivals Introduced As Biosimilars Turnover Falls In Q3
Executive Summary
Organon has launched its Ontruzant trastuzumab biosimilar version of Herceptin and its Aybintio bevacizumab rival to Avastin in Canada. The launches come shortly after the firm revealed biosimilars sales that were slightly down in Q3.
You may also be interested in...
Samsung Bioepis Set To Join High-Concentration Humira Party In Canada
Samsung Bioepis has confirmed launch plans for its citrate-free, high-concentration Hadlima (adalimumab) biosimilar after it was waved through the Canadian healthcare regulator.
IGBA Kicks Off Biosimilars Week With New White Paper
The IGBA has kicked off its third annual global biosimilars week awareness campaign with the release of a white paper that urges stakeholders to recognize and adopt recommendations from the WHO’s latest revised biosimilars guideline.
Fifth US Biosimilar To Herceptin Launched By Merck
Merck & Co has launched Ontruzant, the trastuzumab biosimilar developed and manufactured by Samsung Bioepis, in the US following a staggered approval process and earlier intellectual-property hurdles. The list price discount offered by the firm puts it in the middle of the pack among the four other biosimilar players currently on the market.